New Targeted Radiopharmaceutical Therapy Induces Remission in Pancreatic Cancer Model

Reston, VA (May 13, 2026) -- A newly developed targeted radiopharmaceutical treatment can effectively slow tumor growth in pancreatic ductal adenocarcinoma (PDAC), according to new research published in the May issue of The Journal of Nuclear Medicine. In preclinical models, the treatment achieved complete remission of the disease, highlighting its potential to transform care for this highly aggressive cancer.

PDAC accounts for over 90 percent of pancreatic cancer cases and remains one of the most lethal malignancies, with a five-year survival rate of less than five percent in patients with metastatic disease. Although surgery is the only curative approach, it is feasible only in 10-20 percent of patients with localized disease.

"PDAC is very difficult to treat, and new options are urgently needed," said Marika Nestor, professor in the Department of Immunology, Genetics and Pathology at Uppsala University in Sweden. "Our previous findings suggest a possible new targeted treatment approach for pancreatic cancer patients whose tumors express CD44v6, which may help make treatment more precise and effective."

In the study, researchers evaluated the CD44v6-targeted radiopharmaceutical ¹⁷⁷Lu-AKIR001 as a treatment on its own, as well as paired with standard chemotherapy. CD44v6 expression, radioligand binding, and chemotherapy sensitivity were first assessed in four PDAC cell lines. Next, mice bearing PDAC xenografts received ¹⁷⁷Lu-AKIR001, chemotherapy, or a combination of the two modalities. Therapeutic efficacy and toxicity for each treatment approach were then determined.

Three of the four PDAC cell lines were found to express CD44v6. In the mouse studies, tumor uptake of ¹⁷⁷Lu-AKIR001 was very strong and selective. Tumor growth inhibition was activity-dependent, with complete remissions detected after the administration of 12 MBq of ¹⁷⁷Lu-AKIR001 (40 percent) and four MBq of ¹⁷⁷Lu-AKIR001 combined with paclitaxel chemotherapy (14 percent). No significant toxicity was observed.

"Targeted radiotherapies have already transformed treatment for prostate and neuroendocrine tumors," said Nestor. "Our findings suggest that CD44v6 can be added to the list of targets that can be reached with this approach, and, importantly in a cancer where we desperately need new options."

¹⁷⁷Lu-AKIR001 radiopharmaceutical therapy is currently being evaluated in patients with other malignancies. The clinical program has recently been expanded to allow broader patient inclusion, and this work can help guide how it could be used in the future, according to Nestor.

Figure 2: Biodistribution of [177Lu]Lu-AKIR001. (A) Mice (N = 12) bearing BxPC3 tumors were injected with [177Lu]Lu-AKIR001 and dissected at 24 (N = 4), 96 (N = 4), and 168 h (N = 4) postinjection. Error bars represent SD. (B) Representative SPECT/CT images at 96 h postinjection. GI = gastrointestinal.

The authors of "[¹⁷⁷Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies" include Amanda Gustafsson, Hedvig Svedberg, Sara S. Rinne, and Marika Nestor, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Filippa Bertilsson and Cecilia Lindskog, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Ram Kumar Selvaraju, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; and Anja C. Lundgren Mortensen, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Visit the JNM website for the latest research and follow our Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected].

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.